Haruma Tomoko, Nakamura Keiichiro, Nishida Takeshi, Ogawa Chikako, Kusumoto Tomoyuki, Seki Noriko, Hiramatsu Yuji
Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
Anticancer Res. 2015 Jan;35(1):337-43.
BACKGROUND/AIM: Inflammation and tumor immunology are important in the prognosis of various cancers. We herein investigated whether pre-treatment neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and serum cancer antigen 125 (CA125) predict recurrence and survival in patients with endometrial cancer (EC).
We collected complete blood counts and clinicopathological data from medical records of 320 patients with EC; their pre-treatment NLR, PLR and CA125 were analyzed for correlations with recurrence and survival, retrospectively.
Disease-free survival (DFS) and overall survival (OS) rates of patients with high NLR and CA125 were significantly shorter than those for patients with low NLR and CA125 (DFS: p=0.002 and p<0.001; OS: p<0.001 and p<0.001, respectively). Furthermore, NLR was also an independent predictive factor for mortality in multivariate analysis (hazard ratio (HR)=3.318; 95% confidence interval (CI)=1.154-9.538; p=0.026).
Pre-treatment NLR is a predictor of poor prognosis in EC.
背景/目的：炎症和肿瘤免疫学在各种癌症的预后中起着重要作用。我们在此研究了治疗前中性粒细胞与淋巴细胞比值（NLR）、血小板与淋巴细胞比值（PLR）及血清癌抗原125（CA125）是否可预测子宫内膜癌（EC）患者的复发及生存情况。
我们从320例EC患者的病历中收集了全血细胞计数及临床病理数据；回顾性分析了他们治疗前的NLR、PLR及CA125与复发及生存的相关性。
高NLR和CA125患者的无病生存期（DFS）和总生存期（OS）显著短于低NLR和CA125患者（DFS：p = 0.002和p < 0.001；OS：分别为p < 0.001和p < 0.001）。此外，在多变量分析中，NLR也是死亡率的独立预测因素（风险比（HR）= 3.318；95%置信区间（CI）= 1.154 - 9.538；p = 0.026）。
治疗前NLR是EC患者预后不良的预测指标。
